A biotech all about Alzheimer’s

Dr Bill Ketelbey is the CEO of Actinogen Medical. They’re in the middle of phase two trials for an Alzheimer’s drug called Xanamem. Alan Kohler spoke to Bill to find out more about it.

Become a TCI Community Member Now

Stay up to date and make better informed decisions.
Get access to all this exclusive content and so much more every week!

  • $1 for the first month
  • $25/month membership
  • Cancel anytime, no lock in contract
  • Access to Private Facebook group
  • Smartphone App (coming soon)